tbuckley/cabot-search huggingface dataset:
Abstract 9501: Key Role of Low High Density Lipoprotein Cholesterol for the Association of the Metabolic Syndrome with Inflammation in Patients with Peripheral Arterial Disease
Authors: Philipp Rein, Christoph H Saely, Christian Boehnel, Stefan Beer, Alexander Vonbank, Veronika Kiene, Veronika Drexel, Heinz Drexel
Journal: Circulation (2011)

The association of the metabolic syndrome (MetS) and of the individual MetS stigmata with inflammation in patients with peripheral arterial disease (PAD) has not been investigated yet and is adressed in the present study. We enrolled 410 consecutive patients who underwent routine duplex sonography for the evaluation of suspected or established PAD Fontain stages I-III and in whom PAD was verified sonographically. According to National Cholesterol Education Programme Adult Treatment Panel III criteria, the MetS was defined in the presence of at least 3 out of the 5 quantitatively defined criteria large waist circumference, low HDL cholesterol, high triglycerides, high blood pressure, and elevated fasting glucose. In univariate analyses, CRP was higher in patients with the MetS (n=200) than in those who did not have the MetS (0.94±1.88 vs. 0.56±1.18 mg/dl; p=0.001), and also was higher in patients who fulfilled the large waist (0.93±1.93 vs. 0.59±1.16 mg/dl; p = 0.009) and the low HDL criteria (1.10±1.66 vs. 0.61±1.52 mg/dl; p&lt;0.001) than in those who did not. Importantly however, after adjustment for gender, smoking, BMI and LDL cholesterol by means of ANCOVA only the low HDL cholesterol criterion (F=6.06; p=0.014) remained significantly associated with CRP. The significant and independent association of low HDL with CRP was confirmed after additional adjustment for all other MetS traits (F=7.76; p=0.006). We conclude that among patients with sonographically proven PAD, low HDL cholesterol drives the association between the MetS and subclinical inflammation. This observation is well in line with the paramount role of low HDL cholesterol as a marker of cardiovascular risk.
Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) decrease serum vascular endothelial growth factor (VEGF) of patients with platinum sensitive, advanced ovarian cancer (AOC)
Authors: Francesco Recchia, Alisia Cesta, Giampiero Candeloro, Gaetano Saggio, Antonio Nuzzo, Angelo Lalli, Marco Lombardo, Gaspare Carta, Silvio Rea
Journal: Cancer Research (2005)

6000   Purpose: Patients with advanced ovarian cancer, responsive to chemotherapy and with high serum levels of VEGF have a poor prognosis. In 3 studies (Clin Cancer Res 2001;7:1251-1257, Int J Oncol 2002;20:1275-82, Proc Am Ass Cancer Res 2004;45:1082), we showed that with a low dose of IL-2 and RA we could decrease the VEGF and improve the immune function, with a negligible toxicity profile, in a group of patients with advanced tumors treated with chemotherapy. The primary end-point of this study was to verify if the combination of IL-2 and RA could decrease serum VEGF with respect to baseline values of patients with AOC that had had either a partial (PR) or complete (CR) response or disease stability (SD) after chemotherapy. The secondary end-point was the evaluation of the clinical outcome with respect to a group of historical controls. Patients and methods: 44 patients with platinum sensitive AOC (median age 59 years, stage III 19 patients with a median platinum-free interval of 15 months, stage IV 25 patients), showing a CR, PR or SD to chemotherapy (liposomal doxorubicin and oxaliplatin in 38 patients, high-dose chemotherapy with peripheral blood progenitor cell transplantation in 6 patients) were treated from January 1998 to August 2003 with self-administered subcutaneous IL-2, 1.8 x 10 6  IU and oral RA, 0.5 mg/Kg for 5 days/week for 2 consecutive cycles of 3 weeks, with a 1-week rest, for 1 year and with intermittent schedules, up to 5 years. Controls belonged to a group of 82 patients well matched for all characteristics, treated by members of the IORAM during the same period of time. VEGF, was determined every 2 months, while response was assessed every 4 months. Results: After a median follow-up of 36 months, amongst 44 evaluable patients, a statistically significant decrease of VEGF was observed with respect to baseline values after 6 months (p
Abstract 20091: Instrumental Activities of Daily Living Impairment is an Independent Predictor of Incident Heart Failure, Acute Myocardial Infarction and All-Cause Mortality in Community-Dwelling Older Adults
Authors: C. Barrett Bowling, Ravi V Desai, Mustafa I Ahmed, Margaret A Feller, Marjan Mujib, Kannayiram Alagiakrishnan, Daniel E Forman, Susan J Zieman, Michel White, Gregg C Fonarow, Wilbert S Aronow, Richard M Allman, Ali Ahmed
Journal: Circulation (2010)

Background: Instrumental Activities of Daily Living (IADL) measures physical and cognitive function in older adults and an impaired IADL correlates with poor clinical outcomes. The relationship bet...
Abstract 2016: Levosimendan Infusion in Patients with Myocardial Infarction and High Systemic Vascular Resistance
Authors: Eleftheria P Tsagalou, Maria Anastasiou-Nana, Argyrios Ntalianis, Nikolaos Lazaris, Michail Bonios, Elisavet Kaldara, Eleni Tseliou, Fotis Katsaros, John Nanas
Journal: Circulation (2008)

Background: Levosimendan, a novel inodilator, has been shown to improve hemodynamic function in patients with decompensated heart failure with preserved arterial blood pressure. Data on its use in patients with cardiogenic shock are scarce. The present series describes the 24-h hemodynamic effects of levosimendan as add-on therapy in patients with cardiogenic shock. Methods: Levosimendan was administered for 24 hours (dose ranging from 0.05 to 0.2μg/kg/min), in addition to catecholamines, in 25 patients who suffered from cardiogenic shock after acute myocardial infarction. Hemodynamic measurements were performed at baseline (prior to levosimendan infusion) and at 24 hours after initiation of levosimendan. Results: Hemodynamic improvement was evident only in patients (Group 1, n=13) with increased systematic vascular resistance (SVR&gt;18Wood). Levosimendan administration increased the cardiac index ( 2.1±0.4 l/min/m2 from 1.5±0.3l/min/m2, p=0.002) and cardiac power (0.645±0.179W from 0.462±0.164W, p=0.022) and decreased SVR (21±6.7Wood from 23±5Wood, p=0.001) and pulmonary cappillary wedge pressure (16±11mmHg from 23±5mmHg, p=0.059). On the other hand, patients with low systemic vascular resistance (SVR&lt;19Wood)) (Group B, n=12 ) did not have hemodynamic improvement with levosimendan administration. Conclusions: Levosimendan infusion added to catecholamines in patients with cardiogenic shock after myocardial infarction exerts hemodynamic benefit only in the subgroup of patients with high SVR.
Abstract MP90: Association of Sleep Duration and Quality with Incident Diabetes: Coronary Artery Risk Development in Young Adults Sleep Study
Authors: Mercedes R Carnethon, Peter John D De Chavez, Diane S Lauderdale, April P Carson, Kiang Liu, Kristen L Knutson
Journal: Circulation (2013)

Background: Most prior longitudinal studies investigating the association of sleep characteristics with incident diabetes are based on self-reported sleep duration and quality. However, self-reported sleep is prone to differential error that is based on the amount of actual sleep that a person gets. Objective: To test whether objectively-measured sleep duration and quality or self-reported sleepiness were associated with the development of diabetes in a population sample. Methods: Participants from the Chicago, IL center of the CARDIA study who wore wrist actigraphs (Actiwatch TM ) twice between 2003-2005 and who were free from diabetes in 2000-2001 were included in the analysis (n=594). The following sleep parameters were averaged over 6 days: sleep duration, sleep maintenance (percentage of sleep period actually sleeping) and minutes of wake after sleep onset (WASO). The Epworth Sleepiness Scale (ESS) assessed daytime sleepiness; higher scores reflect more sleepiness. Diabetes was determined based on fasting glucose &gt;126 mg/dL, medication use, post-load glucose &gt;200 mg/dL or Hemoglobin A1c &gt;6.5% during examinations in 2005-2006 and 2010-2011. Results: Participants were 40.1 years old (SD=3.6), average sleep duration was 365.8 min (SD=64.3), sleep maintenance was 88.9% (SD=5.4), WASO was 46.0 min (SD=24.0) and the ESS was 7.5 (SD=4.3). Over ~10 years, 68 participants (11.4%) developed diabetes. Each sleep measure was associated with diabetes incidence in unadjusted models; however, only the association with daytime sleepiness remained significant following adjustment for demographic characteristics and diabetes risk factors. Conclusions: Self-reported daytime sleepiness is a straightforward measurement of sleep quality that can identify adults at risk for diabetes. Although objective measures of sleep duration and quality are associated with incident diabetes, the association is entirely explained by demographic characteristics.
Abstract 808: Elevated Left Ventricular End Diastolic Pressure Predicts New-onset Atrial Fibrillation Following Cardiac Surgery: A Community-based Study
Authors: Rowlens M Melduni, Rakesh M Suri, Charles J Bruce, Hartzell V Schaff, Rick A Nishimura, James B Seward, Bernard J Gersh
Journal: Circulation (2009)

Introduction Atrial fibrillation (AF) is a common complication after cardiac surgery. It is known that abnormal ventriculovascular coupling is a mechanism underlying heart failure. Therefore, we hy...
Regional Nodal Irradiation in Early-Stage Breast Cancer
Authors: Timothy J. Whelan, Ivo A. Olivotto, Wendy R. Parulekar, Ida Ackerman, Boon H. Chua, Abdenour Nabid, Katherine A. Vallis, Julia R. White, Pierre Rousseau, Andre Fortin, Lori J. Pierce, Lee Manchul, Susan Chafe, Maureen C. Nolan, Peter Craighead, Julie Bowen, David R. McCready, Kathleen I. Pritchard, Karen Gelmon, Yvonne Murray, Judy-Anne W. Chapman, Bingshu E. Chen, Mark N. Levine
Journal: New England Journal of Medicine (2015)

Most women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation. We examined whether the addition of regional nodal irradiation to whole-breast irradiation improved outcomes.
Abstract 4375: Potential Effects of Immunoadsorption and Subsequent IgG Substitution on Cardiopulmonary Exercise in DCM Patients
Authors: Lars R Herda, Christiane Trimpert, Astrid Hummel, Ute Nauke, Pfeiffersche Stiftungen, Marcus Dörr, Wolfgang Hoffmann, Ralf Ewert, Stephan B Felix, Alexander Staudt
Journal: Circulation (2008)

Recent data indicate that cardiac antibodies play an active role in the pathogenesis of dilated cardiomyopathy (DCM), and may contribute to cardiac dysfunction of DCM patients. Previous studies have suggested that immunoadsorption with subsequent IgG substitution (IA/IgG) improves left ventricular function in DCM. The potential influence of this immunomodulatory therapy on cardiopulmonary exercise remains to be elucidated. 60 patients with DCM ( n = 60, NYHA II-IV, left ventricular ejection fraction ≤ 45%) underwent either IA/IgG ( n = 30), or were followed up without IA ( n = 30). IA/IgG was performed in one course of five consecutive days. After three months we compared echocardiographic assessment of left ventricular function and spiroergometric exercise parameters in both groups. Left ventricular ejection fraction (LVEF) improved significantly in the IA/IgG group from 33.0 ± 1.2% to 40.1 ± 1.5% (p &lt; 0.001 vs. control, p &lt; 0.001 vs. baseline). In the control group, spiroergometric exercise parameters did not change during follow-up. In contrast, patients receiving IA/IgG improved significantly in the following parameters: peak oxygen uptake (peak VO 2 ; 17.3 ± 0.9 ml/min/kg to 21.8 ± 1.0 ml/min/kg; p &lt; 0.01 vs. control, p &lt; 0.01 vs. baseline), oxygen pulse (10.7 ± 0.7 ml/bpm to 13.6 ± 0.7 ml/bpm; p &lt; 0.05 vs. control, p &lt; 0.01 vs. baseline), and anaerobic threshold (VO 2 AT; 10.3 ± 0.5 ml/min/kg to 13.2 ± 0.5 ml/min/kg; p &lt; 0.001 vs. control, p &lt; 0.001 vs. baseline). The ventilatory response to exercise (V E /VCO 2 slope) decreased after IA/IgG therapy from 32.3 ± 1.5 to 28.7 ± 0.9 (p = 0.18 vs. controls, p = 0.02 vs. baseline), whereas there was no significant change in the control group after 3 months. IA/IgG therapy in DCM patients may induce improvement in echocardiographic and cardiopulmonary exercise parameters.
Abstract 13567: Resting Heart Rate is Associated with C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Venkata Narla, Michael J Blaha, Khurram Nasir, Roger S Blumenthal, Nancy S Jenny, Erin D Michos
Journal: Circulation (2011)

Background: Resting heart rate (HR) is an independent predictor of all-cause and cardiovascular disease (CVD) mortality among individuals with and without prior CVD. The mechanism by which elevated...
Abstract MP050: Race and Gender Group Specific Trends in Length of Stay for Acute Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) study, 1987–2008
Authors: Laura R Loehr, Xiaoxi Liu, C. Baggett, Cameron Guild, Erin D Michos, David Couper, Wayne D Rosamond
Journal: Circulation (2012)

Introduction: Since the 1980’s, length of stay (LOS) for acute MI (AMI) has declined in the US. However, little is known about trends in LOS for non-white racial groups and whether change in LOS is related to insurance type or hospital complications. Methods: We determined 22 year trends in LOS for nonfatal (definite or probable) AMI among black and white residents age 35–74 in 4 US communities (N=396,514 in 2008 population) under surveillance in the ARIC Study. Events were randomly sampled and independently validated using a standardized algorithm. All analyses accounted for sampling scheme. We excluded MI events which started after admission (n=1,677), events within 28 days for the same person (n=3,817), hospital transfers (n=571), and those with LOS=0 or LOS &gt;66 (top 0.5% of distribution, N= 144) leaving 22,258 weighted events for analysis. The average annual change in log LOS was modeled using weighted linear regression with year as a quadratic term. All models adjusted for age and secondary models adjusted for insurance type (Medicare, Medicaid, private, or other), and complications during admission (cardiac arrest, cardiogenic shock, or heart failure). Results: The average age-adjusted LOS from 1987 to 2008 was reduced by 5 days in black men (9.5 to 4.5 days); 4.6 days in white women (9.4 to 4.8 days); 4 days in white men (8.3 to 4.3 days) and 3.6 days in black women (9.0 to 5.4 days). Between 1987 and 2008, the age-adjusted average annual percent change (with 95% CI) in LOS was largest for white men at −4.40 percent per year (−4.91, −3.89) followed by −3.89 percent (−4.52, −3.26) for white women, −3.72 percent (−4.46, −2.89) for black men, and −2.94 percent (−3.92, −1.96) for black women (see Figure). Adjustment for insurance type, and complications did not change the pattern by race and gender. Conclusions: Between 1987 and 2008, LOS for AMI declined significantly and similarly in men and women, blacks and whites. These changes appear independent of differences in insurance type and hospital complications among race-gender groups.
Abstract 20303: Characterization of the Peri-Infarct Zone by Contrast-Enhanced Magnetic Resonance Imaging and 18F-FDG Positron Emission Tomography and its Clinical Impact in Patients with Coronary Artery Disease
Authors: David M Leistner, Sylvia Palm, Ina Ziegler, Inka Diehl, Charlotte Meyer-Woelden, Iris Burck, Birgit Assmus, Florian Seeger, Thomas J Vogl, Andreas M Zeiher
Journal: Circulation (2010)

Introduction: Recent studies emphasizing the prognostic value of the peri-infarct zone have used different CMR methods for quantification of the peri-infarct zone. None of these studies has validat...
Routine Intraoperative Completion Angiography After Coronary Artery Bypass Grafting and 1-Stop Hybrid Revascularization
Authors: David X. Zhao, Marzia Leacche, Jorge M. Balaguer, Konstantinos D. Boudoulas, Julie A. Damp, James P. Greelish, John G. Byrne
Journal: Journal of the American College of Cardiology (2009)
Abstract 5861: BAY 58–2667, A Novel No-independent Activator Of Soluble Guanylate Cyclase Attenuates Myocardial Infarction Following Ischemia/reperfusion Injury Through Protein Kinase G Activation
Authors: Ramzi A Ockaili, Fadi N Salloum, Vinh Q Chau, Sumeet K Lall, Rakesh C Kukreja
Journal: Circulation (2008)

Background: BAY 58–2667 (4-[((4-carboxybutyl){2-[(4-phenethylbenzol) oxy]phenethyl} amino)methyl[benzoic]acid) is a soluble guanylate cyclase (sGC) activator that acts independent of the gaseous ligand NO. Preclinical data show that BAY 58–2667 induces cGMP generation and causes vasodilatation in the diseased vessel. Since cGMP-dependent PKG activation is an essential component of ischemic tolerance induced by preconditioning in the heart, we interrogated the potential role of this compound in cardioprotection. Methods and Results: Adult male ICR mice were pretreated with either BAY 58–2667 (10 μg/kg, ip) or 10% DMSO (vehicle) 30 min prior to regional ischemia for 30 min and reperfusion for 24hrs. PKG-specific inhibitor, KT5283 (1 mg/kg, ip) was given 10 min before BAY 58–2667 or vehicle. Infarct size (IS) was measured by computer morphometry of tetrazolium stained sections. IS (mean ± SE) was reduced with BAY 58–2667 as compared to vehicle (80% reduction). KT5283 blocked the cardioprotective role of BAY 58–2667 as shown by an increase in infarct size. KT5283 alone had no significant effect on infarct size. Similar results were obtained in the rabbit heart where this compound caused 62 % reduction in infarct size following 30 min of ischemia and 3 hrs of reperfusion Conclusion: For the first time, we show that novel NO-independent activator of sGC induces powerful protection against myocardial infarction in the adult heart. The infarct-limiting effect of BAY 58–2667 is mediated by PKG dependent signaling.
Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer.
Authors: E. Schütz, J. Beck, W. M. Mitchell, H. B. Urnovitz
Journal: Journal of Clinical Oncology (2010)

10505 Background: Next generation sequencing provides high numbers of circulating nucleic acid (CNA) serum DNA sequences that can detect trace amounts of these unique serum biomarkers in patients with cancer. The aim of this study was to find signature CNA sequences from patients with breast cancer (BCa) or prostate cancer (PCa) compared to healthy controls, with respect to their predictive potential, as well as to provide new insights into tumor biology. Methods: DNA extracted from serum samples of 178 BCa (Stage 1 and 2), 197 PCa (GS: 3 - 10) and 200 gender and age matched healthy controls (HC) was amplified using random primers, tagged with a unique molecular identifier per sample, sequenced on a 454-Titanium system and aligned to the human genome (Build 37). Hits were counted in 750K interval regions and the 42 best separating chromosome regions selected by a bootstrapped multivariate classification using the Akaike approach to avoid over fitting. These chromosomal regions were used for the subsequent analyses. Results: 1.7 million (BCa), 1.9 million (PCa) and 1.9 million (HC) sequences were generated, representing 0.91 billion nucleotides in total. For BCa a 27-parameter (750k regions) classification yielded a sensitivity of 80% at 96% specificity, whereas a 27-parameter classification for PCa showed 73% vs. 96% respectively. Further analysis revealed a number of small areas (2kbp to 50kbp in length) where hits from cancer samples uniquely clustered. Utilizing these “hot spots”, 92% of BCa and PCa patients and 100% of NC could be classified correctly. There was no overlap between the PCa and BCa specific “hot spots”. Conclusions: Comparative massive parallel sequencing of serum DNA from cancer patients vs. controls has identified unique chromosomal hotspots for PCa and BCa of high sensitivity and specificity amenable to translation to a clinical diagnostic platform. The identified genomic areas in these two distinct carcinomas derived from hormonally regulated epithelium are apparently prone to distinct neoplasm specific genomic anomalies which can be detected in the blood and may provide not only diagnostic improvements to existing screening methods but also potential targets for therapeutic intervention. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Chronix Biomedical Chronix Biomedical Chronix Biomedical
Inactivation of Recombinant Monocyte cAMP-Specific Phosphodiesterase by cAMP Analog, 8-[(4-Bromo-2,3-Dioxobutyl)thio]Adenosine 3′,5′-Cyclic Monophosphate
Authors: George A. Omburo, Theodore J. Torphy, Gilbert Scott, Susanne Jacobitz, Roberta F. Colman, Robert W. Colman
Journal: Blood (1997)
Abstract 11268: Biphasic Character of Aldosterone in Cardiomyocytes Through the Akt Signaling Activation
Authors: Tomohisa Nagoshi, Taro Date, Masami Fujisaki, Takuya Yoshino, Hiroshi Sekiyama, Kazuo Ogawa, Kosuke Minai, Kimiaki Komukai, Takayuki Ogawa, Michihiro Yoshimura
Journal: Circulation (2011)

Aldosterone and Akt signaling both play pivotal roles in the pathogenesis of heart failure; however, little is known about the interaction between them. Here we hypothesized that in cardiomyocytes,...
Abstract 316: Role of an Inflammasome Adaptor Molecule ASC (Apoptosis-associated Speck-like Protein Containing a Caspase Recruitment Domain) in Myocardial Ischemia-Reperfusion Injury
Authors: Masanori Kawaguchi, Masafumi Takahashi, Takeki Hata, Yasuko Takahashi, Hajime Morimoto, Hirohiko Ise, Junji Sagara, Minoru Hongo, Shun’ichiro Taniguchi, Uichi Ikeda
Journal: Circulation (2008)

Inflammatory responses play a key role in the pathophysiology of myocardial ischemia-reperfusion (I/R) injury. ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) is an adaptor protein that forms “inflammasome” whose activation leads to caspase-1-dependent interleukin (IL)-1β generation and subsequent inflammatory responses; however, the role of ASC in myocardial I/R injury remains unclear. Baseline left ventricular (LV) function was unaltered in ASC-deficient (ASC −/− ) mice. ASC −/− (n=42) and wild-type control (WT) (n=42) mice were subjected to 30 min LAD occlusion, followed by reperfusion. ASC −/− mice showed reduced infarct area (infarct area/area at risk: 18.7% vs. 28.6% at 48 h, p&lt; 0.01) and scar formation (scar/LV area: 9.7% vs. 14.6% at 14 days, p&lt; 0.01) after myocardial I/R. Echocardiography showed improved LV dysfunction (%FS: 35.2 vs. 28.4 at 7 days, p&lt; 0.01; 34.0 vs. 25.7 at 14 days, p&lt; 0.01) and dimensions (LVEDD [mm]: 3.88 vs. 4.21 at 7 days, p&lt; 0.01; 3.99 vs. 4.43 at 14 days, p&lt; 0.01) in the ASC −/− mice after myocardial I/R. Immunohistochemistry revealed that infiltration of macrophages (Mac3) and neutrophils (Gr-1) was markedly decreased in the injured myocardium of the ASC −/− mice (48 hr [/mm 2 ]: 1226 vs. 884, p&lt; 0.01; 782 vs. 554, p&lt; 0.01, respectively); however, there was no difference of neovascularization (CD31) in the ischemic area. Double immunofluorescent staining showed that ASC expression was clearly observed in the infiltrated macrophages and neutrophils in the injured myocardium. Real-time RT-PCR analysis demonstrated that the myocardial expression of inflammatory cytokines, such as IL-1β, IL-6, and MCP-1, after I/R were significantly decreased in the ASC −/− mice, compared to that in the WT mice. Further, in vitro experiments showed that LPS-induced production of these inflammatory cytokines in the ASC −/− bone marrow cells was significantly decreased. These findings demonstrate that ASC deficiency prevents inflammatory cell infiltration and cytokine expression, thereby resulting in the improvement of LV dysfunction and remodeling after myocardial I/R injury, and suggest that ASC is a novel therapeutic target for myocardial I/R injury.